Ignite Creation Date:
2024-05-06 @ 3:24 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04629703
Status:
COMPLETED
Last Update Posted:
2023-08-18
First Post:
2020-11-13
Brief Title:
Double-Blind Randomized Placebo-Controlled Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Sponsor:
Rigel Pharmaceuticals
Organization:
Rigel Pharmaceuticals
Organization Data
Organization:
Rigel Pharmaceuticals
Class:
INDUSTRY
Study ID:
C-935788-061
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Rigel Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None